While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compa...

ResMed (RMD) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.81 per share. This compares to earnings of $1.66 per share a year ago.

ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.

Google “How important is sleep?” and you get three billion results.

I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug wi...

Evaluate the expected performance of ResMed (RMD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metric...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.

ResMed is a profitable company with steady growth and attractive margins, making it a solid investment opportunity. The company operates mainly in the sleep apnea market, which is expected to grow ...

ResMed's (RMD) solid revenue growth in the first quarter of fiscal 2024 reflects the strength of AirSense 10 and AirSense 11 sleep devices and robust growth in the mask product portfolio.

ResMed Inc. (NYSE:RMD ) Q1 2024 Results Conference Call October 26, 2023 4:30 PM ET Company Participants Amy Wakeham - Chief Communications and Investor Relations Officer Mick Farrell - Chief Execu...

Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall St...

ResMed (RMD) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.63 per share. This compares to earnings of $1.51 per share a year ago.

ResMed's (RMD) respiratory care business continues to drive growth and the adoption of bilevel and other non-invasive ventilator solutions worldwide.

ResMed (RMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.